Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data.

ABSTRACT: Adalimumab is a fully human monoclonal antibody used for the treatment of inflammatory bowel disease (IBD). Due to its considerably variable pharmacokinetics and the risk of developing antibodies against adalimumab, it is highly recommended to use a model-informed precision dosing approach. The aim of this study is to develop a population pharmacokinetic (PopPK) model of adalimumab for patients with IBD based on a literature model (reference model) to be used in the clinical setting. A retrospective observational study with 54 IBD patients was used to develop two different PopPK models based on the reference model. One of the developed models estimated the pharmacokinetic population parameters (estimated model), and the other model incorporated informative priors (prior model). The models

SUBMITTER: Marquez-Megias S 

PROVIDER: S-EPMC10604709 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature